Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1573-1576

  Da Matta, Vânia Lúcia Ribeiro ^a   Melhem, Márcia De Souza Carvalho ^a   Colombo, Arnaldo Lopes ^b   Moretti, Maria Luiza ^c   Rodero, Laura ^d   De Almeida, Gisele Madeira Duboc ^e   Martins, Marilena Dos Anjos ^a   Costa, Silvia Figueiredo ^e   Dias, Maria Beatriz G Souza ^f   Nucci, Márcio ^g   Levin, Anna S ^e  

^a INSTITUTO ADOLFO LUTZ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f HOSPITAL SÍRIO LIBANÊS   (Brazil)

^g FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BROTH MICRODILUTION METHOD; CLINICAL AND LABORATORY STANDARDS INSTITUTE GUIDELINE; CONCENTRATION RESPONSE; DILUTION; EUROPEAN COMMITTEE ON ANTIBIOTIC SUSCEPTIBILITY TESTING GUIDELINE; FUNGEMIA; FUNGUS ISOLATION; GEOGRAPHIC DISTRIBUTION; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA; PICHIA ANOMALA; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 34247129672     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01038-06     Document Type: Article

References (43)

1. Alter, S. J., and J. Parley. 1994. Development of Hansenula anomala infection in a child receiving fluconazole therapy. Pediatr. Infect. Dis. J. 13:158-159.
2. Aragão, P. A., I. C. Oshiro, E. I. Manrique, C. C. Gomes, L. L. Matsuo, C. Leone, M. L. Moretti-Branchini, and A. S. Levin. 2001. Pichia anomala outbreak in a nursery: exogenous source? Pediatr. Infect. Dis. J. 20:843-848.
3. Bakir, M., N. Cerikcioglii, A. Tirtir, S. Berrak, E. Ozek, and C. Canpolat. 2004. Pichia anomala fungaemia in immunocompromised children. Mycoses 47:231-235.
4. Barchiesi F., A. M Tortorano, L. F. Di Francesco, M. Cogliati, G. Scalise, and M. A. Viviani. 1999. In vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. J. Antimicrob. Chemother. 43:295-299.
5. Barchiesi, F., A. M. Tortorano, L. F. Di Francesco, A. Rigoni, A. Giacometti, E. Spreghini, G. Scalise, and M. A. Viviani. 2005. Genotypic variation and antifungal susceptibilities of Candida pelliculosa clinical isolates. J. Med. Microbiol. 54:279-285.
6. Chakrabarti A., K. Singh, A. Narang, S. Singhi, R. Batra, K. L. N. Rao, P. Ray, S. Gopalan, S. Das, V. Gupta, A. K. Gupta, S. M. Bose, and M. M. McNeil. 2001. Outbreak of Pichia anomala infection in the pediatric service of a tertiary-care center in Northern India. J. Clin. Microbiol. 39:1702-1706.
7. Chryssanthou, E., and M. Cuenca-Estrella. 2002. Comparison of the Anti-fungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J. Clin. Microbiol. 40:3841-3844.
8. Colombo, A. L., Z. Nakagawa, F. Valdetaro, M. L. Branchini, E. J. Kussano, and M. Nucci. 2003. Susceptibility profile of 200 bloodstream isolates of Candida spp. collected from Brazilian tertiary care hospitals. Med. Mycol. 41:235-239.
9. Cuenca-Estrella, M., T. M. Diaz-Guerra, E. Mellado, A. Monzon, and J. L. Rodriguéz-Tudela. 1999. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur. J. Clin. Microbiol. Infect. Dis. 18:432-435.
10. Cuenca-Estrella, M., W. Lee-Yang, M. A. Ciblak, B. A. Arthington-Skaggs, E. Mellado, D. W. Warnock, and J. L. Rodriguez-Tudela. 2002. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob. Agents Chemother. 46:3644-3647.
11. Godoy, P., I. N. Tiraboschi, L. C. Severo, B. Bustamante, B. Calvo, L. P. Almeida, D. A. da Malta, and A. L. Colombo. 2003. Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals. Mem. Inst. Oswaldo Cruz 98:401-405.
12. Haron, E., E. Anaissie, F. Dumphy, K. McCredie, and V. Fainstein. 1988. Hansenula anomala fungemia. Rev. Infect. Dis. 10:1182-1186.
13. Kane, S. L., J. F. Dasta, and C. H. Cook. 2002. Amphotericin B lipid complex for Hansenula anomala pneumonia. Ann. Pharmacother. 36:59-62.
14. Krcmery, V., Jr., E. Oravcova, S. Spanik, M. Mrazova-Studena, J. Trupl, A. Kunova, K. Stopkova-Grey, E. Kukuckova, I. Krupova, A. Demitrovicova, and K. Kralovicova. 1998. Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome. J. Antimicrob. Chemother. 41:373-380.
15. Laverdiere, M., C. Restieri, and F. Habel. 2002. Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods. Int. J. Antimicrob. Agents. 20:468-471.
16. Lopez, F., G. Martin, M. L. Paz, and M. A. Sanz. 1990. Hansenula anomala infection in acute leukemia. Enferm. Infecc. Microbiol. Clin. 8:363-364.
17. Luzzati, R., G. Amalfitano, L. Lazzarini, F. Soldani, S. Bellino, M Solbiati, M. C. Danzi, S. Vento, G. Todeschini, C. Vivenza, and E. Concia. 2000. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur. J. Clin. Microbiol. Infect. Dis. 19:602-607.
18. Marco, F., C. Danes, M. Almela, A. Jurado, J. Mensa, J. P. de la Bellacasa, M. Espasa, J. A. Martinez, and M. T. Jimenez de Anta. 2003. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diagn. Microbiol. Infect. Dis. 46:259-264.
19. Maxwell, M. J., S. A. Messer, R. J. Hollis, L. Boyken, S. Tendolkar, D. J. Diekema, M. A. Pfaller, and the International Fungal Surveillance Participant Group. 2003. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J. Clin. Microbiol. 41:1087-1090.
20. Murphy, N., V. Damjanovic, C. A. Hart, C. R. Buchanan, R. Whitaker, and R. W. I. Cooke. 1986. Infection and colonisation of neonates by Hansenula anomala. Lancet i:291-293.
21. NCCLS/CLSI. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts, 2nd ed. Approved standard, M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
22. Nguyen, M. H., C. J. Clancy, V. L. Yu, Y. C. Yu, A. J. Morris, D. R. Snydman, D. A. Sutton, and M. G. Rinaldi. 1998. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J. Infect. Dis. 177:425-430.
23. Nohinek, B., C. S. Zee-Cheng, W. G. Barnes, L. Dall, and H. R. Gibbs. 1987. Infective endocarditis of a bicuspid aortic valve caused by Hansenula anomala. Am. J. Med. 82:165-168.
24. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdiere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
25. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
26. Pasqualotto, A. C., T. C. Sukiennik, L. C. Severo, C. S. de Amorim, and A. L. Colombo. 2005. An outbreak of Pichia anomala fungemia in a Brazilian pediatric intensive care unit. Infect. Control Hosp. Epidemiol. 26:553-558.
27. Pfaller, M. A., D. J. Diekema, R. N. Jones, H. S. Sader, A. C. Fluit, R. J. Hollis, S. A. Messer, and the SENTRY Participant Group. 2001. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39:3254-3259.
28. Pfaller, M. A., D. J. Diekema, S. A. Messer, and L. Boyken. 2003. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J. Clin. Microbiol. 41:78-83.
29. Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, R. J. Hollis, and R. N. Jones. 2004. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn. Microbiol. Infect. Dis. 48:101-105.
30. Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
31. Pfaller, M. A., S. A. Messer, A. Houston, K. Mills, A. Bolmstrom, and R. N. Jones. 2000. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. J. Clin. Microbiol. 38:3715-3717.
32. Pfaller M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J. Clin. Microbiol. 42:3117-3119.
33. Pfaller, M. A., S. A. Messer, L. Boyken, R. J. Hollis, C. Rice, S. Tendolkar, and D. J. Diekema. 2004. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 48:201-205.
34. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and D. J. Diekema. 2002. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:1723-1727.
35. Qadri, S. M., F. Al Dayel, M. J. Strampfer, and B. A. Cunha. 1988. Urinary tract infection caused by Hansenula anomala. Mycopathologia 104:99-101.
36. Reyes, E., S. Barahona, O. Fischman, M. Niklitschek, M. Baeza, and V. Cifuentes. 2004. Genetic polymorphism of clinical and environmental strains of Pichia anomala. Biol. Res. 37(Suppl.):747-757.
37. Rodríguez-Tudela, J. L., F. Barchiesi, J. Bille, E. Chryssanthou, M. Cuenca-Estrella, D. Denning, J. P. Donnelly, B. Dupont, W. Fegeler, C. Moore, M. Richardson, and P. E. Verweij. 2003. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clin. Microbiol. Infect. 9:i-viii.
38. Sekhon, A. S., K. Kowalewska-Grochowska, A. K. Garg, and W. Vaudry. 1992. Hansenula anomala fungemia in an infant with gastric and cardiac complications with a review of the literature. Eur. J. Epidemiol. 8:305-308.
39. Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411.
40. Stone, J. A., S. D. Holland, P. J. Wickersham, A. Sterrett, M. Schwartz, C. Bonfiglio, M. Hesney, G. A. Winchell, P. J. Deutsch, H. Greenberg, T. L. Hunt, and S. A. Waldman. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745.
41. Thuler, L. C., S. Faivichenco, E. Velasco, C. A. Martins, C. R. Nascimento, and I. A. Castilho. 1997. Fungaemia caused by Hansenula anomala- an outbreak in a cancer hospital. Mycoses 40:193-196.
42. Tortorano, A. M., A. L. Rigoni, E. Biraghi, A. Prigitano, M. A. Viviani, and the FIMUA-ECMM Candidaemia Study Group. 2003. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J. Antimicrob. Chemother. 52:679-682.
43. Wong, A. R., H. Ibrahim, H. Van Rostenberghe, Z. Ishak, and M. J. Radzi. 2000. Hansenula anomala infection in a neonate. J. Paediatr. Child Health 36:1.